Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive ...
Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an ...
Once-daily therapy achieves up to 4.4% placebo-adjusted weight loss, meets all study endpoints and demonstrates favourable ...
The timed run also reduced total review time from almost 26 hours for Enveda’s four reviewers to just under three hours, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results